Organization and Description of the Business
|12 Months Ended|
Dec. 31, 2015
|Organization and Description of the Business|
|Organization and Description of the Business||
Trevena, Inc. (the "Company") was incorporated in Delaware as Parallax Therapeutics, Inc. on November 9, 2007. The Company began operations in December 2007, and its name was changed to Trevena, Inc. on January 3, 2008. The Company is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors. The Company operates in one segment and has its principal office in King of Prussia, Pennsylvania. The Company's revenue has been derived from research grants and a research collaboration with a pharmaceutical company.
At December 31, 2015, the Company had an accumulated deficit of $182.5 million. The net loss was $50.5 million and $49.7 million for the years ended December 31, 2015 and 2014, respectively. The Company expects its cash and cash equivalents of $46.8 million and marketable securities of $125.9 million as of December 31, 2015, together with interest thereon, to be sufficient to fund its operating expenses and capital expenditure requirements into 2018.
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
Reference 1: http://www.xbrl.org/2003/role/presentationRef